This study tests the hypothesis that mifepristone will diminish cognitive distortion and
alleviate psychosis in patients with schizoaffective disorder.
You are invited to participate in a research study which evaluates the effectiveness of
mifepristone (RU 486) in rapidly reducing the symptoms associated with schizoaffective
disorder. Our group believes that the cognitive deficits (a decline in the ability to think
clearly) and psychosis (hallucinations or delusions) exhibited in some affective disorders
are driven by an excess of stress hormone effects (hypercortisolemia). Often the origin of
this hormonal imbalance is unknown. Current treatment for schizoaffective disorder
(characterized by mood swings and hallucinations and/or delusions) involves using a
combination of antidepressant medication (for mood elevation), mood stabilizing medications
(to prevent extreme high and low moods) and antipsychotic medication (for the correction of
altered thinking). While these therapies are often effective, they can take several weeks
or longer to work. We hope to uncover a quick, effective, safe therapy for the treatment of
individuals with your condition.
Inclusion Criteria:The subjects will be 30 inpatients or outpatients with schizoaffective
Exclusion Criteria:Subjects must be between the ages of eighteen and seventy-five without
major medical problems.